Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer
Findings demonstrate worse outcomes for patients with BRCA+ mCSPC treated with available advanced therapies, supporting the need for effective genetically targeted therapies in this population.
Authors
- Carmine Rossi (ORCID: https://orcid.org/0000-0001-5801-6927)
- Sabree Burbage (ORCID: https://orcid.org/0000-0002-5993-3679)
- Benjamin Lowentritt (ORCID: https://orcid.org/0000-0002-2921-6249)
- Dingbo Lin (ORCID: https://orcid.org/0000-0002-7441-8210)
- Mehmet Asım Bilen (ORCID: https://orcid.org/0000-0003-4003-1103)
- Yuxi Wang (ORCID: https://orcid.org/0000-0002-9897-7316)
- Gordon Brown (ORCID: https://orcid.org/0000-0001-8362-7068)
- Ibrahim Khilfeh (ORCID: https://orcid.org/0000-0002-7677-2045)
- Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
- Dominic Pilon (ORCID: https://orcid.org/0000-0002-6093-7167)
- Lilián Díaz (ORCID: https://orcid.org/0009-0006-6397-0129)
Institutions
- Johnson & Johnson (United States) (US)
- Emory University (US)
- New Jersey Urology (US)
- Chesapeake Urology Associates (US)
- Carolina Urologic Research Center (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1007/s12325-025-03270-z
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Flatiron Health
- Johnson and Johnson
- Foundation Medicine